You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
12.22.16
Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
12.22.16
Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS
12.19.16
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C
11.13.16
Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of Rheumatology 2016 Annual Meeting
11.10.16
Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
11.03.16
Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update
11.01.16
Ironwood Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference
10.25.16
Ironwood Highlights Breadth of Gout Research with Presentations at the American College of Rheumatology 2016 Annual Meeting
10.20.16
Ironwood Pharmaceuticals to Host Third Quarter 2016 Investor Update Call
10.03.16
Nine in Ten Physicians Agree Target Goal for Gout Is Imperative, Yet Half of Patients Fail to Reach It, New Survey Shows
10.03.16
Ironwood Announces U.S. Availability of ZURAMPIC® (lesinurad) 200 mg Tablets for Patients with Uncontrolled Gout
09.26.16
Ironwood Closes $150 Million Debt Refinancing
09.07.16
Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
09.01.16
Ironwood Pharmaceuticals to Present at Wells Fargo 2016 Healthcare Conference
08.04.16
Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
07.21.16
Ironwood Pharmaceuticals to Host Second Quarter 2016 Investor Update Call
06.09.16
Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
06.06.16
Ironwood Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
06.03.16
Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad
06.01.16
Ironwood Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
05.18.16
Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference
05.17.16
Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week® 2016
05.09.16
Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update
05.03.16
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference
04.26.16
Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad
04.25.16
Ironwood Pharmaceuticals to Host First Quarter 2016 Investor Update Call
04.07.16
Ironwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors
04.05.16
Ironwood Pharmaceuticals Reports Top-Line Data from Exploratory Phase IIa Study of IW-9179 in Diabetic Gastroparesis
03.30.16
Ironwood Pharmaceuticals to Present Clinical and Preclinical Data on sGC Stimulators at Upcoming Scientific Conferences
03.23.16
Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease
03.09.16
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
03.01.16
Ironwood Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care Conference
02.29.16
Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS® (linaclotide)
02.24.16
Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with Linaclotide for the Treatment of Adults with IBS-C
02.18.16
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update
02.18.16
Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701
02.17.16
Ironwood Pharmaceuticals to Present at 2016 RBC Capital Markets Global Healthcare Conference
02.04.16
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2015 Investor Update Call
01.11.16
Ironwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company
01.04.16
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
MEDIA & INVESTOR RELATIONS CONTACT
Meredith Kaya
617.374.5082
mkaya@ironwoodpharma.com


Latest Tweets